Nick Glover
Directeur/Membre du Conseil chez MEI PHARMA, INC.
Fortune : - $ au 30/04/2024
Profil
Nicholas R.
Glover is an Independent Non-Executive Director at MEI Pharma, Inc. and a Director at Pattern Pharma, Inc. He was previously the President, Chief Executive Officer & Director at YM BioSciences, Inc., Viventia Biotech, Inc., and Sierra Oncology, Inc. Glover also worked as an Investment Manager at Lumira Capital Investment Management, Inc. and an Investment Analyst at University Medical Discoveries, Inc. He holds a graduate degree from the University of British Columbia, a doctorate from Simon Fraser University, and an undergraduate degree from the University of East Anglia.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MEI PHARMA, INC.
-.--% | 30/10/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Nick Glover
| Sociétés | Poste | Début |
|---|---|---|
| MEI PHARMA, INC. | Directeur/Membre du Conseil | 11/06/2013 |
Pattern Pharma, Inc.
 Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nick Glover
| Sociétés | Poste | Fin |
|---|---|---|
| SIERRA ONCOLOGY, INC. | Directeur Général | 22/05/2020 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Directeur Général | 01/02/2013 |
University Medical Discoveries, Inc.
 University Medical Discoveries, Inc. Investment ManagersFinance University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto. | Analyste en capital-investissement | 31/03/2009 |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Directeur Général | 01/06/2008 |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Directeur en chef des Investissements | - |
Formation de Nick Glover
| Simon Fraser University | Doctorate Degree |
| University of East Anglia | Undergraduate Degree |
| University of British Columbia | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MEI PHARMA, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
University Medical Discoveries, Inc.
University Medical Discoveries, Inc. Investment ManagersFinance University Medical Discoveries, Inc. (UMDI) is a venture capital firm located in Toronto. | Finance |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Finance |
Pattern Pharma, Inc.
Pattern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Pattern Pharma, Inc. engages in the pharmaceutical industry. Its product named P2PAR addresses the immune failure which underlies infectious diseases and cancers. The company is headquartered in Toronto, Canada. | Health Technology |
